---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-137861"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:00:13.726346+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics appoints Dr. David Shapiro to Board as Class III director

## Summary
- Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.
- Receives annual cash retainer of $40k for Board service and $5k for Nominating Committee service.
- Received initial option grant of 60k shares (3-year monthly vest) and prorated annual option of 7.5k shares (1-year vest).
- Also appointed to the Nominating and Corporate Governance Committee.

## SEC filing metadata
- accession: 0001193125-26-137861
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/0001193125-26-137861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312526137861/dsgn-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-137861
- JSON: https://secwatch.observer/filing/0001193125-26-137861.json
- Plain text: https://secwatch.observer/filing/0001193125-26-137861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.